INFORMATION BY CANCER TYPE

Immuno oncology

Tecentriq Approved as First-Line Treatment for Some Patients With Bladder Cancer
BY Jason Broderick
The FDA has granted an accelerated approval to Tecentriq as a frontline treatment for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy.
With Immunotherapy, Longer Survival May Come With a Cost in Melanoma
BY Jason Harris
Immunotherapy showed improved survival benefits for stage 3 and 4 melanoma, but it came at a price of greater toxicity, according to a randomized, double-blind phase 3 study that compared 10 mg/kg Yervoy (ipilimumab) or a lower dose of the anti-CTLA-4 anticlonal antibody.
Opdivo Is Promising for Advanced Anal Cancer, Study Shows
BY Jason Harris
The PD-1 inhibitor, Opdivo, may be a promising option for patients with advanced anal cancer, according to a recent study. 
The Future of Immunotherapy for Urothelial Carcinoma Treatment
BY Shannon Connelly
In an interview with CURE, Evan Y. Yu, M.D., discusses the current treatment options for metastatic urothelial carcinoma, the unmet needs that still exist in this space and the possibilities for the future treatment landscape.
Opdivo Exceeds Expectations for Lung Cancer Survival
BY Lauren M. Green
Opdivo (nivolumab) showed better long-term survival rates than expected for patients with metastatic non-small cell lung cancer (NSCLC).
Immunotherapy Drug Improves Overall Survival in Patients With Cervical Cancer
According to a phase II study, an immunotherapy targeting HPV-infected cells led to a one-year survival rate among patients with recurrent metastatic cervical cancer.
Advancing Immunotherapy Impact in Bladder Cancer
BY Gina Columbus
In an interview with CURE, Arlene O. Siefker-Radtke, M.D., discusses immune treatment and the immune landscape for the treatment of patients with urothelial cancers.
Using Evolving Knowledge to Manage Cancer's Side Effects
BY Len Lichtenfeld, M.D.
Should patients avoid immunotherapy because of the side effects that have been reported? Dr. Lichtenfeld shares his thoughts.
Expert Weighs in on Promising New Options for Frontline Kidney Cancer
BY Angelica Welch
David McDermott, M.D. discusses new advances made to treat kidney cancer. 
Kidney Cancer Trial Recommended to Halt
BY Silas Inman
An independent data monitoring committee recommended that the phase 3 ADAPT trial exploring rocapuldencel-T (AGS-003) for the frontline treatment of metastatic renal cell carcinoma (mRCC) be stopped, but Argos Therapeutics explained that they will keep the trial open. 
Special Feature
Share Your Art
Talk about this article with other patients, caregivers, and advocates in the Immuno-oncology CURE discussion group.
Search Cancer Drugs & Terms
x